“Tumour Microenvironment Modulation to Overcome Checkpoint Resistance: Where the Preclinical Rationale Holds” (2026) Translational Medicine & Therapeutics Journal, 5(2), pp. 28–36. doi:10.5281/zenodo.22649559.